![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety and Efficacy at 4 Years in Post-Liver Transplant Patients With Chronic Kidney Disease Receiving Tenofovir Alafenamide [vs TDF] for HBV Prophylaxis
|
|
|
AASLD 2021 Nov 12-15
Edward J. Gane,1 Bibin George,1 Dominic Ray-Chaudhuri,1 Thomas Mules,1 Curtis D. Holt,2 Hongyuan Wang,2 Vithika Suri,2 Anuj Gaggar,2 Anu 0. Osinusi,2 John F. Flaherty2
'New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland. New Zealand; 2Gilead Sciences, Inc. Foster City, CA
![1120211](../images/112021/112021-8/1120211.gif)
![1120212](../images/112021/112021-8/1120212.gif)
![1120213](../images/112021/112021-8/1120213.gif)
![1120214](../images/112021/112021-8/1120214.gif)
![1120215](../images/112021/112021-8/1120215.gif)
![1120216](../images/112021/112021-8/1120216.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|